On October 16, 2026, a clinical trial update was recorded for NCT05894239. The trial is titled "A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer." It is a Phase 3 study, and its current status is listed as recruiting.
This update pertains to inavolisib and Phesgo, not to gonadorelin. No event data was provided linking gonadorelin to this specific trial. The trial record does not include any results, efficacy data, or safety findings in the information supplied. Only the trial title, phase, status, and date are reported here.
Readers interested in gonadorelin, which carries approved regulatory status, should note that this particular update does not reflect a study of that compound. For accurate context on gonadorelin itself, including its approved uses and any associated trial activity, consult the compound overview.